Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies December 4, 2024
Cancer Targeted Technology Receives Fast Track $2.4M Grant to Develop an Innovative PSMA-Targeted Small Molecule Drug Conjugate for Prostate Cancer November 26, 2024
Incyclix Bio and Lilly to test INX-315 + Verzenio and Fulvestrant in HR+/HER2- Breast Cancer November 26, 2024
Ratio Therapeutics Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate November 26, 2024
Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline November 26, 2024
VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific ADC November 26, 2024
Vyriad announces strategic collaboration with Novartis to develop in vivo CAR-T cell therapies November 26, 2024
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias November 26, 2024
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer November 26, 2024
Transposon Therapeutics Strengthens and Expands Development Pipeline with the Acquisition of a Portfolio of Novel Nucleoside Analogs for Oncology November 26, 2024
IDEAYA Nominates IDE034, a B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen November 19, 2024
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib November 19, 2024
ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors November 19, 2024
Xenetic Biosciences Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform November 13, 2024
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize SC ENHERTU® Enabled by Alteogen’s Hybrozyme™ Technology November 12, 2024
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA (fruquintinib) Sales by Takeda November 5, 2024
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Gen Cancer Biotherapeutics November 5, 2024
Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals November 5, 2024
Revitope Enters into a License Agreement with Genmab for Next-gen T Cell Engagement Technology November 5, 2024
